Seqirus is first-to-market with shipment of seasonal influenza vaccines to the US for the 2016-2017 season

Tuesday, July 12, 2016 Child Health News J E 4
NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

HOLLY SPRINGS, N.C., July 11, 2016 /PRNewswire/ -- Seqirus announced today that it has begun shipment of its portfolio of influenza vaccines to customers in the US market for the 2016-2017 season. The vaccines include Fluad® (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent® (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine).  

About SeqirusSeqirus is the new global company created in July 2015 from the combined strength and expertise of bioCSL Inc. and the influenza vaccines business formerly owned by Novartis AG. As the second largest influenza vaccine provider in the world, Seqirus is driven by the promise it shares with parent company, CSL Limited, to provide medicines that help to protect and save lives.

Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally, with extensive research and production expertise and manufacturing plants in the US, Europe and Australia and a commercial presence in 20 countries.

Seqirus is part of CSL Limited (ASX:CSL), headquartered in Melbourne, Australia. The CSL Group of companies employ more than 16,000 people with operations in more than 30 countries.

For more information visit and

Media Contact:

Monica Galimberti                                                                           Global Communications, Seqirus                 Phone: +39 335 7440521 (mobile)            

To view the original version on PR Newswire, visit:

SOURCE Seqirus



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Adrienne Handley is recognized by Continental Who'...
EpiCast Report: Idiopathic Pulmonary Fibrosis - Ep...